Steven Garth Potkin
Physician in Irvine, CA

2008024, Oct 2, 2008

Oct 12, 2007

11/974516

Steven Potkin - Irvine CA, US
James H. Fallon - Irvine CA, US
Fabio Macciardi - Milano, IT
Jessica Turner - Irvine CA, US
David Keator - Ladera Ranch CA, US

The Regents of the University of California - Oakland CA

C12Q 1/68

435 6

Methods of assigning quantitative phenotype measurement summary statistics to differential brain image information associated with neuropsychiatric disorders are provided. Summary statistics are correlated to genotype information to identify loci that correlate with differential brain image phenotypes. Methods of identifying modulators of genes at the loci are provided, as well as modulators identified by the methods. Systems for correlating polymorphisms and differential brain image phenotypes, for identifying modulators and for making correlations between differential brain activation phenotypes and genotypes are also provided.

2009029, Dec 3, 2009

Dec 1, 2005

11/721145

Jogeshwar Mukherjee - Irvine CA, US
Ramaiah Pichika - Astoria OR, US
Steven Potkin - Irvine CA, US
Frances Leslie - Irvine CA, US
Sankha Chattopadhyay - Kolkata, IN

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

A61K 51/04, C07D 401/02, A61K 49/00, A61P 25/00, A61P 35/00

424 165, 5462764, 5462681, 424 91

Contemplated compositions and methods are employed to bind in vitro and in vivo to an α4β2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with α4ββ2 dysfunction.

2009006, Mar 12, 2009

Aug 30, 2007

11/847458

Michel Bourin - Nantes, FR
Daniel E. Casey - Portland OR, US
Steven G. Potkin - Irvine CA, US
Mark Rapaport - Los Angeles CA, US
John Newcomer - St. Louis MO, US
Paul P. Yeung - Southeastern PA, US
Sangeeta Raje - Collegeville PA, US
Jeff Paul - Collegeville PA, US
Saeed Ahmed - Collegeville PA, US
Luigi M. Barbato - Alpharetta GA, US
Nathan A. Shapira - Atlanta GA, US
Roseline Pardue - Marietta GA, US
Antje A. Winsemius - Weesp, NL
Michiel H. de Vries - Weesp, NL
Marc Debelle - Valby-Copenhagen, DK
Jens Heisterberg - Valby-Copenhagen, DK
Mette Krog Josiassen - Valby-Copenhagen, DK
Jette Buch Ostergard - Valby-Copenhagen, DK
Dorte Malling - Valby-Copenhagen, DK
Ellen B. Christensen - Valby-Copenhagen, DK

A61K 31/496, A61K 33/00, A61K 31/4525, A61K 31/4196

424722, 51425402, 514321, 514383, 51425407

The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.

2006002, Jan 26, 2006

Jan 5, 2005

11/030584

Scott McDonald - Chatham NJ, US
Ivan Gergel - Malvern PA, US
Steven Potkin - Irvine CA, US
Albrecht Stoffler - Frankfurt am Main, DE
Yvonne Wirth - Marburg, DE
Hans-Joerg Moebius - Frankfurt, DE

Forest Laboratories, Inc. - New York NY

A61K 31/13

514662000

The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain in subjectes with mild, or mild-to-moderate Alzheimer's disease.

2011007, Mar 24, 2011

Nov 19, 2010

12/949944

Michel BOURIN - Nantes, FR
Daniel E. Casey - Portland OR, US
Steven G. Potkin - Irvine CA, US
Mark Rapaport - Los Angeles CA, US
John Newcomer - St. Louis MO, US
Paul P. Yeung - Southeastern PA, US
Sangeeta Raje - Collegeville PA, US
Jeff Paul - Collegeville PA, US
Saeed Ahmed - Collegeville PA, US
Luigi M. Barbato - Alpharetta GA, US
Nathan A. Shapira - Atlanta GA, US
Roseline Pardue - Marietta GA, US
Antje A. Winsemius - Weesp, NL
Michiel H. de Vries - Weesp, NL
Marc Debelle - Valby-Copenhagen, DK
Jens Heisterberg - Valby Copenhagen, DK
Mette Krog Josiassen - Valby-Copenhagen, DK
Jette Buch Ostergard - Valby-Copenhagen, DK
Dorte Malling - Valby-Copenhagen, DK
Ellen B. Christensen - Valby-Copenhagen, DK

A61K 31/496, A61K 33/00, A61P 25/18, A61P 3/04

424722, 51425402

The present disclosure is directed to compositions, kits and methods for not only treating schizophrenia, e.g., maintaining, reducing and/or improving at least one symptom of schizophrenia, but also to achieving an absence of or a reduced presence of at least one side effect associated with schizophrenia therapy with a first-generation atypical antipsychotic.

2010004, Feb 25, 2010

Oct 29, 2009

12/608046

Scott McDonald - Chatham NJ, US
Ivan Gergel - Malvern PA, US
Steven Potkin - Irvine CA, US
Albrecht Stöffler - Frankfurt Am Main, DE
Yvonne Wirth - Marburg, DE
Hans-Joerg Moebius - Frankfurt, DE

FOREST LABORATORIES HOLDINGS LIMITED - Hamilton

A61K 31/13, A61P 25/28

514661

The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain in subjects with mild, or mild-to-moderate Alzheimer's disease.